RTN-001

DB05615InvestigationalSmall molecule

SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

Mechanism: Pharmacologically active on cGMP-specific 3',5'-cyclic phosphodiesterase
Curator reviewed
Primary indication: Investigated for use/treatment in cardiovascular disorders, erectile dysfunction, hypertension, and raynaud's disease.Curator reviewed
Code names: RTN-001 · SLx-2101

Resolves to

Targets

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with RTN-001, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.